This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,
progressive. Progression of IPF is reflected by a decline in lung function, worsening of …

Background: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the
progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled …

Rationale Patients with fibrotic interstitial lung disease (ILD) frequently develop resting or
exertional hypoxaemia. There is heterogeneity in clinical practice and a paucity of evidence …

International treatment guidelines for idiopathic pulmonary fibrosis (IPF) give a conditional
recommendation for anti-acid therapy. As some observational studies reported discrepant …

Domiciliary oxygen therapy is often prescribed for patients with hypoxaemia due to
advanced lung disease, most commonly chronic obstructive pulmonary disease (COPD) and …

The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic
pulmonary fibrosis (IPF), and increased our understanding of the underlying disease …

Introduction: This document presents the guidelines of the Polish Respiratory Society
(PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic …

Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic
pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased …

Highlights The working group of the Polish Respiratory Society (PTChP) developed
guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A …